418 related articles for article (PubMed ID: 9272340)
1. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
Taranger J; Trollfors B; Knutsson N
Dev Biol Stand; 1997; 89():109-12. PubMed ID: 9272340
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of a pertussis-toxoid vaccine.
Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB
N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047
[TBL] [Abstract][Full Text] [Related]
3. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
[TBL] [Abstract][Full Text] [Related]
4. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
6. Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials.
Ciofi degli Atti ML; Olin P
Dev Biol Stand; 1997; 89():77-81. PubMed ID: 9272334
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of one whole-cell and three acellular pertussis vaccines in Stockholm trial II.
Heijbel H; Rasmussen F; Olin P
Dev Biol Stand; 1997; 89():99-100. PubMed ID: 9272337
[No Abstract] [Full Text] [Related]
8. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
9. Common side effects in the Italian and Stockholm I trials.
Tozzi AE; Olin P
Dev Biol Stand; 1997; 89():105-8. PubMed ID: 9272339
[TBL] [Abstract][Full Text] [Related]
10. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
Stehr K; Cherry JD
Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
[No Abstract] [Full Text] [Related]
11. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies.
Heijbel H; Ciofi degli Atti M; Harzer E; Liese J; Preziosi MP; Rasmussen F; Schmitt HJ; Storsaeter J; Taranger J; Uberall M; Tozzi AE
Dev Biol Stand; 1997; 89():101-3. PubMed ID: 9272338
[No Abstract] [Full Text] [Related]
12. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
13. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
Halperin SA; King J; Law B; Mills E; Willems P
Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
[TBL] [Abstract][Full Text] [Related]
16. The Gothenburg pertussis vaccine study.
Trollfors B; Taranger J
Dev Biol Stand; 1997; 89():49-51. PubMed ID: 9333568
[No Abstract] [Full Text] [Related]
17. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
Halperin SA; Eastwood B; Barreto L; Mills E; Blatter M; Reisinger K; Bader G; Keyserling H; Roberts EA; Guasparini R
Scand J Infect Dis; 1995; 27(3):279-87. PubMed ID: 8539554
[TBL] [Abstract][Full Text] [Related]
18. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
19. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
20. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
